Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W-135 and Y conjugate vaccine (GSK, f23484)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal group A, C, W-135 and Y conjugate vaccine (specifically the version marketed by GSK as Menveo) is a quadrivalent vaccine indicated for active immunization to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. It consists of purified capsular polysaccharides from these four serogroups, each individually conjugated to a non-toxic mutant of diphtheria toxin carrier protein (CRM197). This conjugation converts the T-cell independent polysaccharides into T-cell dependent antigens, which significantly enhances immunogenicity and induces immunological memory, particularly in infants and young children. In the context of respiratory syncytial virus (RSV) research, this vaccine has been utilized as an active comparator or co-administered vaccine in clinical trials (such as NCT03636906) evaluating investigational RSV candidates like ChAd155-RSV to assess safety, reactogenicity, and potential immune interference.
- Brand names
- Menveo
- Other names
- Quadrivalent meningococcal conjugate vaccineMenACWY vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, W-135 and Y conjugate vaccine (GSK, f23484).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W-135 and Y conjugate vaccine (GSK, f23484).